Inmode Ltd (INMD) Stock Price, Quote & News

Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well a...

Industry: Medical Devices

Sector: Healthcare

Phone: 972 4 909 6313

Website: www.inmodemd.com

Address:

Tavor Building, Sha’ar Yokneam PO Box 533, Yokne'am, Israel

hgarrett Sep. 11 at 4:55 PM

$INMD started here

0 · Reply

romroc25 Sep. 10 at 3:46 PM

$INMD cash up the ying and yang with no place to go. Who does that?

0 · Reply

findingthestock Sep. 10 at 3:23 PM

$INMD Continued revised downward guidance and sitting on cash for extended period of time will spook investors and the financials won’t matter and stock price will go nowhere

0 · Reply

_StockFox_ Sep. 10 at 1:35 PM

I buy weakness and then relax while people chase..maybe not most people's cup of tea but works for me great and keeps my money safe..WITH PATIENCE... New adds for today: $TZOO $INMD $VMEO $MED

0 · Reply

Capitalism_daddy Sep. 10 at 1:02 PM

$INMD Very detailed letter from large shareholder. Using super transparant wording and phrasing, a delight to read. Hopefully they act upon it.

0 · Reply

findingthestock Sep. 10 at 10:22 AM

$INMD The market is watching, as are investors. InMode's board must do the right thing for shareholders, working to return the cash sitting on the balance sheet, and creating value for the Company's true owners. Sincerely, Pedro Escudero CEO & CIO DOMA Perpetual Capital Management LLC

0 · Reply

findingthestock Sep. 10 at 10:16 AM

$INMD InMode's valuation has continued to contract. We believe this is partly due to management's chaotic leadership; one reason sales remain low is the detrimental decision to fire the head of sales for the US – the Company's largest market – without a clear plan for leadership and to increase sales in the region.i The Company's reputation and valuation suffer from management's consistent damaging comments regarding capital allocation, including CEO Moshe Mizrahy's recent assertion that buybacks have not been a good investment for shareholders and have shown no results https://www.prnewswire.com/news-releases/doma-perpetual-sends-letter-urging-board-of-directors-of-inmode-ltd-to-return-capital-to-the-shareholders-302550020.html

0 · Reply

findingthestock Sep. 8 at 7:06 PM

$INMD the gains won’t be much Will use funds to find better growth stocks and get in at lower avg and attain MORE SHARES

0 · Reply

Shortsnightmare Sep. 8 at 6:52 PM

$INMD On the verge of a major breakout. Technically and fundamentally…..

0 · Reply

findingthestock Sep. 8 at 5:35 PM

$INMD How down is everyone? I am hoping this can get $21 and I can exit

1 · Reply

DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Return Capital to the Shareholders

Sep 2, 2025, 8:30 AM EDT - 10 days ago

InMode to Present at Baird 2025 Global Healthcare Conference

Aug 5, 2025, 8:30 AM EDT - 5 weeks ago

InMode to Participate in Upcoming Investor Conferences

Jul 30, 2025, 3:22 PM EDT - 6 weeks ago

InMode Ltd. (INMD) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:00 AM EDT - 6 weeks ago

InMode Reports Second Quarter 2025 Financial Results: Quarterly Revenue of $95.6 Million, 80% Gross Margins

Jul 12, 2025, 8:08 AM EDT - 2 months ago

InMode: Margin Pressure, But Optionality Makes It Worth A Look

Jul 10, 2025, 7:00 AM EDT - 2 months ago

InMode to Report Second Quarter 2025 Financial Results and Hold Conference Call on July 30, Expects Q2 Revenue Between $95.4M-$95.5M, Decreases Full Year 2025 Revenue Guidance to be Between $365M-$375M

May 28, 2025, 8:30 AM EDT - 3 months ago

InMode Response Letter to DOMA by Moshe Mizrahy, CEO, Dated May 28, 2025

May 9, 2025, 8:22 AM EDT - 4 months ago

DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program

May 7, 2025, 8:30 AM EDT - 4 months ago

InMode to Present at Upcoming Investor Conferences and Events

May 6, 2025, 8:03 AM EDT - 4 months ago

InMode Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges

Apr 29, 2025, 7:00 AM EDT - 4 months ago

InMode Q1 Earnings: Short-Term Catalysts Have Vanished (Rating Downgrade)

Apr 29, 2025, 1:52 AM EDT - 4 months ago

InMode: Equity Value Hinges On Cash, Not Future Prospects (Rating Downgrade)

Apr 28, 2025, 1:41 PM EDT - 4 months ago

Eyes On Park Introduces Revolutionary Envision by InMode System for Advanced Dry Eye Treatment in New York City

Apr 28, 2025, 11:53 AM EDT - 4 months ago

InMode Ltd. (INMD) Q1 2025 Earnings Call Transcript

Apr 28, 2025, 7:00 AM EDT - 4 months ago

InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease

Apr 3, 2025, 4:26 AM EDT - 5 months ago

InMode: Strategic Capital Allocation Unlocks Shareholder Value (Rating Upgrade)

Mar 26, 2025, 8:30 AM EDT - 6 months ago

InMode to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 6, 2025, 7:30 AM EST - 6 months ago

InMode Responds to Doma Perpetual's Letters

Mar 3, 2025, 8:30 AM EST - 6 months ago

InMode to Present at Upcoming Investor Conferences

Feb 10, 2025, 1:14 AM EST - 7 months ago

InMode: Plastic Surgery Boom, Cash Flow, And Cheap

Feb 6, 2025, 9:08 AM EST - 7 months ago

InMode Ltd. (INMD) Q4 2024 Earnings Call Transcript

Feb 4, 2025, 7:00 AM EST - 7 months ago

InMode Reports Fourth Quarter and Full Year 2024 Financial Results; Board of Directors Has Approved a New Share Repurchase Program

Feb 3, 2025, 8:30 AM EST - 7 months ago

InMode to Participate in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference

Jan 28, 2025, 9:32 AM EST - 8 months ago

InMode: A Clear Bargain With Unique Risks

Jan 16, 2025, 7:00 AM EST - 8 months ago

InMode to Report Fourth Quarter & Full Year 2024 and Hold Conference Call on February 4, 2025, Earlier than Originally Announced

Jan 15, 2025, 8:05 AM EST - 8 months ago

DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Immediately Execute Tender Offer followed by Share Buyback

Jan 10, 2025, 6:07 AM EST - 8 months ago

InMode: Clearly, I Was Too Optimistic (Rating Downgrade)

Jan 8, 2025, 7:00 AM EST - 8 months ago

InMode to Report Fourth Quarter & Full Year 2024 Financial Results and Hold Conference Call on February 6, 2025, Expects Q4 Revenue Between $97.0M-$97.5M

Dec 12, 2024, 1:17 AM EST - 9 months ago

InMode: Product Origination And Undervaluation Make The Stock A Buy

Nov 5, 2024, 9:43 AM EST - 11 months ago

InMode: $25/Share Is Closer Than You Think

Oct 31, 2024, 12:16 PM EDT - 11 months ago

InMode: A Deep Dive After Q3 Earnings

Oct 30, 2024, 11:33 AM EDT - 11 months ago

InMode Ltd. (INMD) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:00 AM EDT - 11 months ago

InMode Reports Third Quarter 2024 Financial Results; Quarterly GAAP Revenue of $130.2 Million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024)

Oct 24, 2024, 7:03 AM EDT - 11 months ago

InMode Granted Preliminary Injunction Against Online Sellers Prohibiting Counterfeit Sales of Morpheus8 Radiofrequency Devices and Cartridge Accessories

Oct 10, 2024, 7:00 AM EDT - 1 year ago

InMode to Report Third Quarter 2024 Financial Results and Hold Conference Call on October 30, 2024

Oct 4, 2024, 8:00 AM EDT - 1 year ago

Stock Picks From Seeking Alpha's September 2024 New Analysts

AME CCL CRWD CUK DVN EGO EMR

Oct 1, 2024, 7:00 AM EDT - 1 year ago

InMode Announces Departures of President of North America, Chief Medical Officer and VP of Sales USA as Part of a Global Reorganization Strategy

Sep 19, 2024, 7:14 AM EDT - 1 year ago

InMode Offers High Risk-Reward Opportunity Amid New Products And Rate Cuts (Rating Upgrade)

Sep 10, 2024, 7:00 AM EDT - 1 year ago

InMode Announces Share Repurchase Program of Up to 7.68 Million Shares

Sep 6, 2024, 4:38 AM EDT - 1 year ago

InMode Stock: An Inverse Bubble Caused By Short-Term Trouble

Sep 4, 2024, 8:30 AM EDT - 1 year ago

InMode to Present at 2024 Baird Global Healthcare Conference

Aug 1, 2024, 11:19 AM EDT - 1 year ago

InMode Ltd. (INMD) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 7:00 AM EDT - 1 year ago

InMode Reports Second Quarter 2024 Financial Results; Quarterly Revenue of $86.4M Represents 36.5% Year-Over-Year Decrease; Pro Forma Revenue (including new platform pre-orders not yet delivered) of $102.6M

Jul 31, 2024, 8:03 AM EDT - 1 year ago

InMode Introduces IgniteRF The Complete Minimally Invasive Soft Tissue Contraction Platform

Jul 25, 2024, 8:15 AM EDT - 1 year ago

DOMA Perpetual Sends Letter to the Board of Directors of InMode Urging the Execution of a 40% Tender Offer

Jul 17, 2024, 8:03 AM EDT - 1 year ago

Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling

Jul 11, 2024, 8:30 AM EDT - 1 year ago

InMode to Report Second Quarter 2024 Financial Results and Hold Conference Call on Aug. 1, 2024

Jun 13, 2024, 11:49 AM EDT - 1 year ago

InMode: Reversing Previous Shareholder Dilution With Buybacks

May 16, 2024, 8:00 AM EDT - 1 year ago

InMode to Present at Jefferies Healthcare Conference

hgarrett Sep. 11 at 4:55 PM

$INMD started here

0 · Reply

romroc25 Sep. 10 at 3:46 PM

$INMD cash up the ying and yang with no place to go. Who does that?

0 · Reply

findingthestock Sep. 10 at 3:23 PM

$INMD Continued revised downward guidance and sitting on cash for extended period of time will spook investors and the financials won’t matter and stock price will go nowhere

0 · Reply

_StockFox_ Sep. 10 at 1:35 PM

I buy weakness and then relax while people chase..maybe not most people's cup of tea but works for me great and keeps my money safe..WITH PATIENCE... New adds for today: $TZOO $INMD $VMEO $MED

0 · Reply

Capitalism_daddy Sep. 10 at 1:02 PM

$INMD Very detailed letter from large shareholder. Using super transparant wording and phrasing, a delight to read. Hopefully they act upon it.

0 · Reply

findingthestock Sep. 10 at 10:22 AM

0 · Reply

findingthestock Sep. 10 at 10:16 AM

0 · Reply

findingthestock Sep. 8 at 7:06 PM

$INMD the gains won’t be much Will use funds to find better growth stocks and get in at lower avg and attain MORE SHARES

0 · Reply

Shortsnightmare Sep. 8 at 6:52 PM

$INMD On the verge of a major breakout. Technically and fundamentally…..

0 · Reply

findingthestock Sep. 8 at 5:35 PM

$INMD How down is everyone? I am hoping this can get $21 and I can exit

1 · Reply

romroc25 Sep. 2 at 7:43 PM

$INMD Great stock, but in petrified hands

0 · Reply

findingthestock Sep. 2 at 3:16 PM

$INMD Other than Moshe and management being replaced how can this stock move upwards. No one is buying InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will present in-person at the Baird 2025 Global Healthcare Conference in New York on Sept. 10, 2025. The fireside chat, moderated by Jeff Johnson, Senior Research Analyst, is scheduled for 8:30 am Eastern Time on Wednesday, Sept. 10, and a live webcast of the presentation can be accessed here. InMode will also hold one-on-one investor meetings in person that same day. To schedule a meeting, please contact your Baird representative

0 · Reply

findingthestock Aug. 29 at 8:39 PM

$INMD if this crosses $15.50+ I will buy more and and avg down Buying when upward trend Been burned with this stock too many times when it looks like it going to go up only to sink down and down

0 · Reply

Shortsnightmare Aug. 29 at 4:59 PM

$INMD Current FWL P/E on the S&P 500 in 22X. INMD is an above average company as measured by margins, growth prospects, ROIC, balance sheet strength, free cash flow etc. Consensus estimates for next year are 1.70 per share. At 22X that equates to a $37 share price. Add in $9 per share net cash and you get $46. A triple from here…..

0 · Reply

findingthestock Aug. 28 at 3:08 PM

$INMD that was short lived below $15 Ridiculous Get rid of Moshe

0 · Reply

newscatch Aug. 27 at 10:07 PM

$INMD https://www.consultingroom.com/industry/blog/inmode-uk-announce-launch-and-expansion-of-new-digital-and-marketing-department

0 · Reply

findingthestock Aug. 27 at 7:05 PM

$INMD This stock has been horrible and management is horrible but I still wanting and hoping to get out and break even So hopefully this is an upward trend Nuveen LLC purchased a new stake in shares of InMode in the first quarter worth about $4,444,000. Institutional investors own 68.04% of the company's stock.

0 · Reply

Winning_calls Aug. 27 at 3:42 PM

$INMD 🤞🤞🤞

0 · Reply

findingthestock Aug. 27 at 3:02 PM

$INMD Finally some decent movement

0 · Reply

Awiz2 Aug. 27 at 2:42 PM

$INMD Its Time!!!! its time to accelerate past $20 and begin its climb into mid $30S

0 · Reply

Shortsnightmare Aug. 26 at 4:55 PM

$INMD INMD math: $550 million in net cash currently. $68 million in inventory currently which at an 80 pct gross margin converts into $68/(1-0.80) = $340 million in cash ‘on sale’. That is $890 million in effective cash. The company has zero debt! Currently there are 61 million shares outstanding at $14.70 which is $890 million in market value! You are getting the company for free at the current price. Not to mention this puts zero value on all its patents and it’s hugely profitable, capital light, free cash flow generating business. Do the math yourself. The stock price will not stay this low when smart value investors start to do the same math…..the same when PE firms start doing the math.

2 · Reply

Shortsnightmare Aug. 26 at 3:53 PM

$INMD At the current level of FCF generation ($100 million per annum) which is a cyclical low, the entire market value of the company will be in cash on INMDs balance sheet in 3 years. With no debt. And the business, which is a market leader, will be free. Run the numbers for yourselves and get long while this anomaly exists.

0 · Reply

Market Cap	949.40M
Revenue (ttm)	394.82M
Net Income (ttm)	181.28M
EPS (ttm)	N/A
PE Ratio	8.81
Forward PE	10.84
Profit Margin	45.91%
Debt to Equity Ratio	0.00

Volume	827,400
Avg Vol	1,065,406
Day's Range	N/A - N/A
Shares Out	63.21M
Stochastic %K	88%
Beta	2.00
Analysts	Hold
Price Target	$16.25